How Rosuvastatin (Crestor) Affects AST Levels

Rosuvastatin (brand name Crestor) works by inhibiting HMG-CoA reductase to lower LDL cholesterol and reduce cardiovascular risk. As a statin, it received FDA approval for these cholesterol-management goals. Here we focus on how rosuvastatin affects AST (aspartate aminotransferase), a liver enzyme routinely measured alongside ALT on standard hepatic panels.

The direct answer

Rosuvastatin can raise AST through a pharmacologic effect on hepatocytes, not through a distinct toxic metabolite; most elevations are mild, appear within the first three months of therapy, and reverse after the dose is lowered or the drug is stopped. Elevations large enough to prompt stopping the drug are uncommon across the approved dose range (5 mg to 40 mg), and rosuvastatin has not been shown in large trials to cause more serious liver injury than placebo. This is a class effect shared, in some degree, by other statins, and it is distinct from statin-associated muscle injury, which can also raise AST through a non-hepatic route.

What AST does and does not tell you on a statin

AST is not liver-specific. It is present in the liver, heart, skeletal muscle, kidneys, and red blood cells. A rise in AST on its own does not prove liver injury.

Statins work inside hepatocytes by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. This intracellular metabolic effect can produce transient membrane changes that let small amounts of AST and ALT (alanine aminotransferase) leak into the blood. ALT is more liver-specific than AST, so pairing the two values matters more than looking at AST alone.

Rosuvastatin can also cause statin-associated muscle symptoms in a subset of patients, and muscle injury raises AST independent of any liver effect. When AST rises but ALT stays normal, muscle, heart, or red blood cell turnover is a more likely source than the liver. When both AST and ALT rise together, a liver-origin cause becomes more probable. The AST/ALT ratio (sometimes called the De Ritis ratio) is a rough clinical heuristic here, not a diagnostic test: a ratio clearly above 2:1 with normal ALT points away from hepatocellular injury, while a ratio near 1:1 with both enzymes elevated points toward it.

Does rosuvastatin raise AST, and by how much?

Yes, rosuvastatin can raise AST, and the effect described in the drug's labeling and in the published statin-safety literature is generally dose-related: higher doses (40 mg) are associated with a somewhat higher rate of transaminase elevation than lower doses (5 to 20 mg). The FDA-approved prescribing information for Crestor describes persistent elevation of hepatic transaminases as an uncommon but recognized adverse effect and instructs prescribers to obtain hepatic function tests before starting therapy and as clinically indicated afterward (FDA label, revision current as of 2023; confirm the version in effect at the time of prescribing, since labels are periodically updated).

Beyond that qualitative pattern, this draft does not carry forward specific incidence percentages (for example, "0.3%" or "0.5%") because the underlying citation for those numbers could not be independently verified against the primary literature for this rewrite. A reader or clinician who needs an exact number for shared decision-making should pull it directly from the current FDA label or a recent statin-safety guideline rather than from a secondary summary, including this one.

What is well established across the statin class, including rosuvastatin, is the general shape of the risk: most AST elevations are mild, most appear early in treatment, and most resolve without permanent liver injury when the drug is stopped or the dose reduced. Serious drug-induced liver injury from statins, when it occurs, is rare, but this article does not carry forward a precise per-patient-year rate, because the specific figure cited in earlier drafts of this topic could not be traced to a verifiable primary source.

When do AST changes on rosuvastatin usually appear?

Most transaminase changes attributed to statins, including rosuvastatin, emerge within the first several weeks to about three months of starting or increasing the dose. This is consistent with a pharmacologic adaptation process in hepatocytes as the liver adjusts to reduced cholesterol synthesis and increased LDL receptor expression, a mechanism tied to rosuvastatin's selective uptake into liver cells via the OATP1B1 and OATP1B3 transporters.

Basic-science work continues to refine how OATP1B1 transport activity is regulated at the cellular level, including recent research on enzymatic control of OATP1B1 function (Regulation of OATP1B1 transport by lysine deacetylase 6, 2026). This is preclinical, mechanistic research; it helps explain why rosuvastatin concentrates its metabolic effect in the liver, but it does not by itself establish a specific clinical AST incidence or monitoring interval in patients, and should not be read as clinical evidence about how often AST rises or by how much.

An AST elevation that appears for the first time after many months of stable therapy is less likely to be a straightforward statin effect and deserves a broader workup: new medications, alcohol use, viral hepatitis, biliary disease, and autoimmune liver disease should all be considered before attributing a late rise to rosuvastatin alone.

What current practice says about monitoring

Statin-safety guidance has moved away from mandating routine, periodic liver function testing for every patient on a statin. The general pattern described in guideline literature and reflected in FDA labeling is: check hepatic function before starting the drug, and recheck if the dose changes or if the patient develops symptoms suggestive of liver injury (fatigue, right upper quadrant pain, dark urine, jaundice, unusual bruising). This represents current guideline-level practice as commonly described in the statin-safety literature; a reader who wants the exact wording of a specific society's current recommendation should verify it against that society's most recent published statement, since guidance can be updated.

A practical framework for interpreting an AST change on rosuvastatin

The table below is a decision aid, not a substitute for individualized clinical judgment. It organizes the tradeoffs a clinician typically weighs when an AST result comes back abnormal on rosuvastatin.

This framework describes reasoning patterns drawn from general statin-safety literature and the FDA's approach to drug-induced liver injury signals; it is not a diagnostic algorithm and does not replace a clinician's evaluation of an individual patient's full picture, including other medications, alcohol use, and baseline liver disease.

Special situations that change the picture

Pre-existing fatty liver disease (NAFLD/MASLD). Patients with fatty liver disease often start with higher baseline transaminases and may be more likely to cross a concerning threshold on any statin, including rosuvastatin. Current hepatology guidance generally does not support withholding statins from patients with fatty liver disease, because cardiovascular disease is a leading cause of death in this population; the standard approach is closer monitoring rather than avoidance, but the specific interval a clinician chooses should be individualized.

Patients of Asian ancestry. The FDA label for rosuvastatin recommends a lower starting dose in Asian patients because of increased systemic drug exposure linked to differences in hepatic transporter activity. This is a labeled dosing consideration, not evidence of a different AST monitoring schedule by itself, and should be discussed with the prescribing clinician.

Interacting drugs. Cyclosporine, gemfibrozil, and certain other drugs can meaningfully raise rosuvastatin blood levels, and the label restricts or contraindicates higher rosuvastatin doses in combination with some of these agents. Anyone starting a new interacting medication while on rosuvastatin should have this reviewed by a pharmacist or prescriber rather than assuming the prior dose remains appropriate.

Heavy alcohol use. Alcohol-related liver disease can produce an AST/ALT pattern that looks similar to what is sometimes attributed to statins. A clinician evaluating an abnormal result on rosuvastatin in a patient who drinks heavily should not assume the statin is the cause without considering alcohol as a competing explanation.

What is established, what is plausible, and what is not established

Established: Rosuvastatin can cause mild, usually early, usually reversible elevations in AST and ALT through a direct hepatocyte effect; this is described in FDA labeling and reflected across the general statin-safety literature. ALT is a more liver-specific marker than AST, and isolated AST elevation with normal ALT often has a non-hepatic explanation, particularly muscle.

Plausible but not fully quantified in this draft: Precise incidence rates for AST elevation at each rosuvastatin dose, and precise rates of serious statin-related liver injury, are reported in the literature but the specific figures could not be verified against a traceable primary source for this rewrite. These numbers should be pulled from the current FDA label or a current guideline document before being used in patient counseling.

Not established here: This article does not establish an individualized dosing or monitoring schedule for any specific patient. Decisions about starting, continuing, holding, or stopping rosuvastatin based on an AST result should be made by the prescribing clinician with the patient's full history, other lab values (including ALT and, when muscle symptoms are present, creatine kinase), and current guideline recommendations in hand.

When to seek care rather than wait for a routine recheck

Symptoms such as jaundice, dark urine, pale stools, right upper quadrant pain, fatigue, or unexplained bruising or bleeding during rosuvastatin therapy should prompt immediate medical attention rather than deferral until the next scheduled lab appointment. Similarly, new muscle pain or weakness requires prompt evaluation and a creatine kinase measurement, as muscle injury can elevate AST independently while also indicating a rosuvastatin-related myopathy.

This article is a draft prepared for editorial and qualified medical review and has not yet received that review. Specific incidence figures, monitoring intervals, and dosing decisions should be confirmed against current FDA labeling and applicable clinical guidelines before use in patient care.